Drug profile · INN
levonorgestrel
KYLEENA
levonorgestrel (KYLEENA) is a progesterone receptor agonist. Associated with Lacuna Pharma Pty Ltd. Route of administration: implantation. Current US regulatory status: approved.
Drug details — levonorgestrel
- US status
- approved
- Class
- —
- Route
- IMPLANTATION
- Patents
- 2
- Programs
- 14
- Data quality
- 0.84
Quick answer
levonorgestrel (KYLEENA) is a progesterone receptor agonist. Associated with Lacuna Pharma Pty Ltd. Route of administration: implantation. Current US regulatory status: approved.
Key facts
Mechanism of action
Progesterone receptor agonist
Primary target: Progesterone receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| TGA | approved | — |
Pipeline programs
- Levonorgestrel 100 mcg and Ethinyl Estradiol 20 mcg
- Levonorgestrel/EE 0.15/0.03 mg and EE 0.01 mg tablets
- Mirena 20 mikrogram/24 timmar intrauterint in...
- Seasonale (levonorgestrel and ethinyl estradiol)
- Seasonale [levonorgestrel (LNG)/ethinyl estradiol (EE)]
- levonorgestrel/EE 0.15/0.03 and EE 0.01 mg tablets
- 91-day Levonorgestrel Oral Contraceptive
- 91-day Levonorgestrel Oral Contraceptive
Related & competitor drugs
Related patents
Frequently asked questions
What is levonorgestrel?
levonorgestrel (KYLEENA) is a progesterone receptor agonist. Associated with Lacuna Pharma Pty Ltd. Route of administration: implantation. Current US regulatory status: approved.
What is the brand name for levonorgestrel?
KYLEENA is a marketed brand name for levonorgestrel. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of levonorgestrel?
levonorgestrel has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.